Celltrion is a biopharmaceutical company that has successfully developed and launched a number of biosimilars globally. These include Omlyclo (omalizumab), Celltrion's biosimilar of the reference product Xolair [1], Remsima (infliximab) which references Remicade [2], Herzuma (trastuzumab) which references Herceptin) [3], and Steqeyma (ustekinumab) which references Stelara [4].

According to the agreement, Hasten will also own the marketing authorisation holder (MAH) rights for products in eight countries and regions, including South Korea, Singapore, Thailand, Australia, and China Hong Kong. 

The products include Actos, Edarbi, Nesina, Basen, and Blopress, all of which were acquired by Celltrion from Takeda in 2020 [5].

It is hoped that the deal will enrich Hasten's product pipeline across the countries and into regions outside mainland China. Combined with a more qualified global supply chain and a quality management system, the move is likely to pave the way for access to more high-quality products in the Pan-Asia Area. As the acquisition lays a solid foundation for the company's business expansion in Pan-Asia, Hasten is well positioned to become a leader in the chronic disease ecosystem. 

Related articles
FDA BLA updates from Celltrion and Accord

FDA approves Zymfentra and advances for Yuflyma in the US

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of first omalizumab biosimilar Omlyclo [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-first-omalizumab-biosimilar-omlyclo
2. GaBI Online - Generics and Biosimilars Initiative. EMA approves first monoclonal antibody biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/EMA-approves-first-monoclonal-antibody-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. EC approval for trastuzumab biosimilar Herzuma [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/EC-approval-for-trastuzumab-biosimilar-Herzuma
4. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of four ustekinumab biosimilars: Eksunbi, Fymskina, Otulfi, Steqeyma [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-four-ustekinumab-biosimilars-eksunbi-fymskina-otulfi-steqeyma
5. GaBI Online - Generics and Biosimilars Initiative. Celltrion: Takeda acquisitions and new plant development [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/pharma-news/Celltrion-Takeda-acquisitions-and-new-plant-development

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.